Christine Fang Gelin

USPTO Granted Patents = 25 (Patent Applications = 5)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 5.6

ph-index = 8

Forward Citations = 177(Granted Patents)

Company Filing History:

22 out of 2,079

Janssen Pharmaceutica Nv

1 out of 832,912

Other

patents

Years Active: 2014-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12247027 - P2X7 modulators (2025-03-11),

2. 12172997 - Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators (2024-12-24),

3. 11820770 - P2X7 modulators (2023-11-21),

4. 11618750 - Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators (2023-04-04),

5. 11530210 - Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators (2022-12-20),

6. 11459336 - Pyrazine carbamates and their use as GluN2B receptor modulators (2022-10-04),

7. 11447503 - Pyridine carbamates and their use as GLUN2B receptor modulators (2022-09-20),

8. 11225478 - P2X7 modulators (2022-01-18),

9. 11161846 - Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators (2021-11-02),

10. 10766880 - Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators (2020-09-08),

11. 10703749 - P2X7 modulators (2020-07-07),

12. 10233173 - Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators (2019-03-19),

13. 10183953 - Substituted 2-azabicycles and their use as orexin receptor modulators (2019-01-22),

14. 10150765 - P2X7 modulators (2018-12-11),

15. 10112937 - P2X7 modulators and methods of use (2018-10-30),

Title: Christine Fang Gelin: A Pioneer in Receptor Modulation

Introduction

Christine Fang Gelin, a prominent inventor based in San Diego, California, stands out for her significant contributions to the fields of pharmaceutical science and receptor modulation. With an impressive portfolio of 24 patents, Gelin has dedicated her career to advancing healthcare solutions through innovative chemical compounds.

Latest Patents

Among her latest inventions are the "Substituted Pyrazolo-Pyridine Amides and Their Use as GluN2B Receptor Modulators." These compounds serve as crucial modulators of the GluN2B receptor, offering potential therapeutic benefits for diseases and disorders linked to this receptor's activity. Another notable patent is for "P2X7 Modulators," which encompasses specific compounds known as Formulas (I, IIa, and IIb). This invention also includes related pharmaceutical compositions and methods for both the production and application of these compounds in medical treatments.

Career Highlights

Christine has worked with leading pharmaceutical companies, including Janssen Pharmaceutica NV and Novartis AG. Her invaluable contributions during her tenure at these organizations have paved the way for advancements in understanding and treating receptor-related conditions.

Collaborations

Throughout her career, Gelin has collaborated with esteemed professionals such as Curt A. Dvorak and Brice M. Stenne. These partnerships have allowed for the creative exchange of ideas and expertise, further enhancing her innovative approaches in the field.

Conclusion

Christine Fang Gelin's work in developing receptor modulators showcases her dedication to innovation in the pharmaceutical industry. Her patents reflect a commitment to addressing complex health issues, making her a key figure among contemporary inventors in this critical area of research.

This text is generated by artificial intelligence and may not be accurate.